Roni Mamluk, Ph.D., joined our Board of Directors in June 2017. She previously served as the company’s Chief Development Officer from March 2015 to April 2017 and currently serves as our Head of Development through her appointment to the board of directors of our subsidiary, Chiasma (Israel) Ltd. She served as Chief Executive Officer of Chiasma from April 2013 to March 2015 and held various roles of increasing responsibility, including Chief Operating Officer and Vice President, Research and Development, from 2006 to April 2013. She also served as a member of our Board of Directors from April 2013 to March 2015. Since joining us, Dr. Mamluk has played a leading role in developing, and is one of the primary inventors of, our proprietary Transient Permeability Enhancer, or TPE®, technology platform. She has also led the development of oral octreotide and ongoing improvements to our TPE platform. Dr. Mamluk joined us from Adnexus Therapeutics, Inc., where she established and led nonclinical research and development. Dr. Mamluk received her B.A. and Ph.D. from the Hebrew University. She also participated in a post-doctoral fellowship at Boston Children’s Hospital/Harvard Medical School in the field of angiogenesis. We believe Dr. Mamluk’s extensive knowledge of Chiasma’s business and TPE technology as our former Chief Development Officer and former Chief Executive Officer as well as her experience in the biopharmaceutical industry qualify her to serve on our Board of Directors.